drugset / Trial / NCT00496808
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
NaSingle-groupOpen-labelTreatment
Summary
Primary Objectives: * To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) * To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu over-expressing DCIS
Timeline
- Start
- 2005-03
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 8 mg/kg | Intravenous |